MiCardia CE marks enCor heart valve repair device
This article was originally published in Clinica
Executive Summary
MiCardia’s enCor mitral valve repair system is now available in Europe after the firm CE marked it. It is intended for patients with mitral valve regurgitation, where the mitral valve in the heart does not close tightly, allowing blood to flow backwards. The device, an annulosplasty ring, can be adjusted during surgery to correct any residual mitral valve regurgitation in real time on a beating heart. Irvine, California-based MiCardia is also developing a next-generation device, enCorSQ, which clinicians can adjust during minimally invasive surgery. It is designed to treat recurrent regurgitation weeks, months or years after the initial surgery. Around 20,000 mitral valve repair procedures are performed in Europe each year, MiCardia estimates.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.